(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 0 474 517 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
18.11.1998 Bulletin 1998/47

(51) Int. Cl.[6]: **A61K 31/59**

(21) Application number: **91308205.3**

(22) Date of filing: **09.09.1991**

(54) **Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis**

Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis

Nouvelle utilisation de composés 1-alpha-hydroxylés de la 19-nor vitamine D pour traiter le psoriasis

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: **07.09.1990 US 579935**

(43) Date of publication of application:
11.03.1992 Bulletin 1992/11

(73) Proprietor:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Madison, WI 53705 (US)

(72) Inventor: **DeLuca, Hector Floyd**
Deerfield, Wisconsin 53531 (US)

(74) Representative:
Ellis-Jones, Patrick George Armine et al
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

(56) References cited:
EP-A- 0 387 077 **WO-A-89/10351**

- **TETRAHEDRON LETTERS, vol. 31, no. 13, 3rd April 1990, pages 1823-1824, Pergamon Press plc; K.L. PERLMAN et al.: "1alpha,25-dihydroxy-19-nor-vitamin D3, a novel vitamin D-related compound with potential therapeutic activity"**

EP 0 474 517 B1

Description

Background of the Invention

The present invention relates to vitamin D compounds, and more particularly to the use of 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis.

The D vitamins are very important agents for the control of calcium and phosphate metabolism in animals and humans, and have long been used as dietary supplements and in clinical practice to assure proper bone growth and development. It is now known that the in vivo activity of these vitamins, specifically of vitamin D_2 and D_3, is dependent on metabolism to hydroxylated forms. Thus, vitamin D_3 undergoes two successive hydroxylation reactions in vivo, leading first to 25-hydroxyvitamin D_3 and then to 1,25-dihydroxyvitamin D_3 and the latter is indeed thought to be the compound responsible for the well-known beneficial effects of vitamin D_3. Likewise, vitamin D_2, which is commonly used as a dietary supplement, undergoes an analogous hydroxylation sequence to its active forms, being first converted to 25-hydroxyvitamin D_2 (25-OH-D_2) and then to 1,25-dihydroxyvitamin D_2 (1,25-$(OH)_2D_2$). These facts are well established and well known in the art (see, for example, Suda et al. Biochemistry 8, 3515 (1969) and Jones et al. Biochemistry 14, 1250 (1975)).

Hollick, U. S. Patent No. 4,728,643 discloses a method of treating psoriasis with vitamin D compounds which in vitro cause cell differentiation. However 1α-hydroxylated vitamin D compounds, i.e. those compounds having only a hydroxyl group at the carbon 1 position and initially lacking a hydroxyl group at the carbon 24 or 25 positions, are relatively inactive in causing cell differentiation in vitro. Additionally, it is also well known that 1α-hydroxylated compounds are rapidly converted in vivo to 1α,25-dihydroxy compounds, e.g. 1α-hydroxyvitamin D_3 to 1α,25-dihydroxy-vitamin D_3, or if the 25 carbon position is blocked to 1α,24-dihydroxy compounds. Hollick et al, Science, Vol. 190, pages 576-578 (1975) and Hollick et al, J. of Clinical Endocrinology & Metabolism, Vol. 44., pages 595-598 (1977). For example, in PCT patent application number PCT/DK89/00079 filed April 7, 1989 and published November 2, 1989 under number WO89/10351 there is disclosed numerous side chain homologated vitamin D compounds lacking the hydroxyl group at the carbon 25 position in the side chain. It is disclosed therein that such compounds are converted in vivo to active compounds having a hydroxyl group at the carbon 25 position by enzymatic hydroxylation, and may thus be used for the treatment of psoriasis. Thus, the human body can rapidly convert relatively inactive 1α-hydroxylated vitamin D compounds to metabolites highly active in causing cell differentiation. There has, however, been a failure in the art to recognize the ability of 1α-hydroxylated-19-nor-vitamin D compounds to treat malignancies such as psoriasis.

Tetrahedron Letters, Vol 31, No. 13, pp 1823-4, 1990 discloses 1α,25-dihydroxy-19-nor-vitamin D_3 and its use in the treatment of malignancies while EP-A-0387077, which forms part of the state of the art by virtue of Article 54(3) EPC, discloses a class of 19-nor vitamin D compounds but none of these contains a triple bond in the side chain.

Summary of the Invention

Compositions containing one or more 1α-hydroxylated-19-nor-vitamin D compounds with a triple bond in the side chain which compounds when administered to humans are converted to a metabolite, which metabolite in vitro has cell differentiation activity, together with a suitable carrier useful in the treatment of psoriasis are described. The treatment may be topical, oral or parenteral. Methods of employing the compositions are also disclosed. The compounds are present in the composition in an amount from about 0.01 μg/gm to about 100 μg/gm of the composition, and may be administered orally or parenterally in dosages of from about 0.01 μg/day to about 100 μg/day.

The compounds disclosed herein unexpectedly provide highly effective treatments for psoriasis without producing unwanted systemic or local side effects.

Detailed Description of the Invention

The vitamin D compounds useful in the compositions of the present invention and for the treatment of psoriasis are those which are solely 1α-hydroxylated, i.e. those that do not initially have a hydroxyl group at the 24 or 25 carbon position in the side chain. Such 1α-hydroxylated compounds are readily converted to 1α,25-dihydroxy or 1α,24-dihydroxy compounds in vivo. These dihydroxy compounds are highly potent in inducing cellular differentiation, and the preferred compounds are those which induce cellular differentiation with minimal or no effect on either intestinal calcium absorption or bone calcium mobilization. Accordingly, specific preferred examples of vitamin D compounds defined by the above functions are those selected from the group consisting of 1α-hydroxy-19-nor-vitamin D compounds.

The 1α-19-nor-vitamin D compounds referred to herein are a class of 1α-hydroxylated vitamin D compounds in which the ring A exocyclic methylene group (carbon 19) typical of all vitamin D systems has been removed and replaced by two hydrogen atoms. Structurally these novel analogs are characterized by the general formula II shown below:



II

where X and Y are each selected from the group consisting of hydrogen, acyl, alkylsilyl and alkoxyalkyl, and where the group U represents the following side chain:



wherein R_1 and R_2 are each selected from the group consisting of alkyl, hydroxyalkyl and fluoroalkyl, deuteroalkyl or, when taken together represent the group -- $(CH_2)_m$ -- where m is an integer having a value of from 2 to 5, R_3 is selected from the group consisting of hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl and fluoroalkyl, R_6 is selected from the group consisting of hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl and fluoroalkyl, or, R_3 and R_6 taken together represent double-bonded oxygen or double-bonded carbon, R_4 and R_5 taken together form a carbon-carbon triple bond i.e. a carbon-carbon triple bond is formed between the two carbon atoms, and wherein n is an integer having a value of from 1 to 5, and wherein the carbon at any one of positions 20, 22 or 23 in the side chain may be replaced by an O, S, or N atom with the proviso that when R_3 is other than hydroxy or O-acyl at least one of R_3 and R_6 is hydrogen or deuterium.

As used herein "alkyl" represents a straight-chain or branched hydrocarbon radical of 1 to 10 carbons in all its isomeric forms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and pentyl, and the terms "hydroxyalkyl", "fluoroalkyl" and "deuteroalkyl" refer to such an alkyl radical substituted by one or more hydroxy or fluoro or deuterium groups respectively. An acyl group is an alkanoyl group of 1 to 6 carbons in all its isomeric forms, or an aroyl group, such as benzoyl, or halo-, nitro- or alkyl-substituted benzoyl groups, or a dicarboxylic acyl group such as oxalyl, malonyl, succinoyl, glutaroyl, or adipoyl. The term "aryl" signifies a phenyl-, or an alkyl-, nitro- or halo-substituted phenyl group.

It should be noted in this description that the term "24-dihomo" refers to the addition of two methylene groups at the carbon 24 position in the side chain. Likewise, the term "trihomo" refers to the addition of three methylene groups. Also, the term "26,27-dimethyl" refers to the addition of a methyl group at the carbon 26 and 27 positions so that for example R_1 and R_2 are ethyl groups. Likewise, the term "26,27-diethyl" refers to the addition of an ethyl group at the 26 and 27 positions so that R_1 and R_2 are propyl groups.

The preparation of 1α-hydroxy-19-nor-vitamin D compounds having the basic structure shown above in formula II can be accomplished by a common general method, using known vitamin D compounds as starting materials. Suitable starting materials are, for example, the vitamin D compounds of the general structure IV:



IV

where U is any of the side chains as defined above. These vitamin D starting materials are known compounds, or compounds that can be prepared by known methods.

Using the procedure of DeLuca et al U.S. Patent 4,195,027, the starting material is converted to the corresponding 1α-hydroxy-3,5-cyclovitamin D derivative, having the general structure V below, where X^3 represents hydrogen and Q represents an alkyl, preferably methyl:



V

So as to preclude undesired reaction of the 1α-hydroxy group in subsequent steps, the hydroxy group is converted to the corresponding acyl derivative, i.e. the compound V shown above, where X^3 represents an acyl group, using standard acylation procedures, such as treatment with an acyl anhydride or acyl halide in pyridine at room temperature or slightly elevated temperature (30-70°C). It should be understood also that whereas the process of this invention is illustrated here with acyl protection of hydroxy functions, alternative standard hydroxy-protecting groups can also be used, such as, for example, alkylsilyl or alkoxyalkyl groups. Such protecting groups are well-known in the art (e.g. trimethylsilyl, triethylsilyl, t.-butyldimethylsilyl, or tetrahydrofuranyl, methoxymethyl), and their use is considered a routine modification of experimental detail within the scope of the process of this invention.

The derivative as obtained above is then reacted with osmium tetroxide, to produce the 10,19-dihydroxy analog, VI (where X^3 is acyl), which is subjected to diol cleavage using sodium metaperiodate or similar vicinal diol cleavage reagents (e.g. lead tetraacetate) to obtain the 10-oxo-intermediate, having the structure VII below (where X^3 is acyl):



VI



VII

These two consecutive steps can be carried out according to the procedures given by Paaren et al. (J. Org. Chem. 48, 3819 (1983)). If the side chain unit, U carries vicinal diols (e.g. 24,25-dihydroxy- or 25,26-dihydroxy, etc.), these, of course, also need to be protected, e.g. via acylation, silylation, or as the isopropylidene derivative prior to the periodate cleavage reactions.

In most cases, the acylation of the 1α-hydroxy group as mentioned above will simultaneously effect the acylation of side chain hydroxy functions, and these acylation conditions can, of course, be appropriately adjusted (e.g. elevated temperatures, longer reaction times) so as to assure complete protection of side chain vicinal diol groupings.

The next step of the process comprises the reduction of the 10-oxo-group to the corresponding 10-alcohol having the structure VIII shown below (where X^3 is acyl and Y^3 represents hydroxy). When X^3 is acyl, this reduction is carried out conveniently in an organic solvent at from about 0°C to about room temperature, using $NaBH_4$ or equivalent hydride reducing agents, selective for the reduction of carbonyl groups without cleaving ester functions. Obviously, when X^3 is a hydroxy-protecting group that is stable to reducing agents, any of the other hydride reducing agents (e.g. $LiAlH_4$, or analogous reagents) may be employed also.



VIII

The 10-hydroxy intermediate is then treated with an alkyl-or arylsulfonylhalide (e.g. methanesulfonylchloride) in a suitable solvent (e.g. pyridine) to obtain the corresponding 10-0-alkyl-or arylsulfonyl derivative (the compound having the structure shown VIII above, where Y^3 is alkyl-SO_2O-, or aryl-SO_2O-, and this sulfonate intermediate is then directly reduced, with lithium aluminum hydride, or the analogous known lithium aluminum alkyl hydride reagents in an ether solvent, at a temperature ranging from O°C to the boiling temperature of the solvent, thereby displacing the sulfonate group and obtaining the 10-deoxy derivative, represented by the structure VIII above, where X^3 and Y^3 are both hydrog n. As shown by the above structure, a 1-0-acyl function in the precursor compound VII is also cleaved in this reduction step to produce the free 1α-hydroxy function, and any 0-acyl protecting group in the side chain would, of course,

likewise be reduced to the corresponding free alcohol function, as is well understood in the art. If desired, the hydroxy groups at C-1 (or hydroxy groups in the side chain) can be reprotected by acylation or silylation or ether formation to the corresponding acyl, alkylsilyl or alkoxyalkyl derivative, but such protection is not required. Alternative hydroxy-protecting groups, such as alkylsilyl or alkoxyalkyl groups would be retained in this reduction step, but can be removed, as desired, at this or later stages in the process by standard methods known in the art.

The above 1α-hydroxy-10-deoxy cyclovitamin D intermediate is next solvolyzed in the presence of a low-molecular weight organic acid, using the conditions of DeLuca et al U.S. Patents 4,195,027 and 4,260,549. When the solvolysis is carried out in acetic acid, for example, there is obtained a mixture of 1α-hydroxy-19-nor-vitamin D 3-acetate and 1α-hydroxy-19-nor-vitamin D 1-acetate (compounds IX and X, below), and the analogous 1- and 3-acylates are produced, when alternative acids are used for solvolysis.



IX



X

Direct basic hydrolysis of this mixture under standard conditions then produces the desired 1α-hydroxy-19-nor-vitamin D compounds of structure II above (where X^1 and Y^1 are both hydrogen). Alternatively, the above mixture of monoacetates may also be separated (e.g. by high pressure liquid chromatography) and the resulting 1-acetate and 3-acetate isomers may be subjected separately to hydroxysis to obtain the same final product from each, namely the 1α-hydroxy-19-nor-vitamin D compounds of structure II. Also the separated monoacetates of structure IX or X or the free 1,3-dihydroxy compound can, of course, be reacylated according to standard procedures with any desired acyl group, so as to produce the product of structure II above, where X^1 and Y^1 represent acyl groups which may be the same or different.

Compositions for use in the above-mentioned treatment of psoriasis comprise an effective amount of one or more 1α-hydroxy-19-nor-vitamin D compounds as defined by the above formula II as the active ingredient, and a suitable carrier. An effective amount of such compounds for use in accordance with this invention is typically from 0.01 μg to 100 μg per gm of composition, and may be administered topically, orally or parenterally in dosages of from, say, 0.1 μg/day to 100 μg/day.

The compounds may be formulated as creams, lotions, ointments, topical patches, pills, capsules or tablets, or in liquid form as solutions, emulsions, dispersions or suspensions in pharmaceutically innocuous and acceptable solvent or oils, and such preparations may contain in addition other pharmaceutically innocuous or beneficial components, such as antioxidants or preserving agents, stabilising, wetting or emulsifying agents, solution promoters, coloring agents, binders or coating materials.

The compositions of this invention are typically formulated as a foam (which may contain a propellant), a stick, a cleansing pad, an impregnated wipe, a face pack, a shaving foam or an after shave, but preferably as creams, lotions or ointments by choice of appropriate carriers. Suitable carriers may be solid or liquid and include vegetable or mineral oils such as corn starch, lactose, sucrose, peanut oil, olive oil and sesame oil, propylene glycol, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C_{12}). The preferred carriers are those in which the active ingredient is soluble. Thickening agents (so that the composition is in the form of an ointment, cream, lotion or gel), other active cosmetic ingredients including anti-wrinkle agents and anti-grease agents along with additives such as surfactants, soaps, bath additives, organic solvents, emulsifiers, stabilizers and antioxidants may also be included as well as agents imparting color or fragrance if desired.

Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil such as almond oil, is admixed. A typical example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.

Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with

warm soft paraffin and allowing the mixtur to cool. A typical example of such an intment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.

Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.

The compounds may be administered topically, as oral doses, or parenterally by injection or infusion of suitable sterile solutions. The compounds are advantageously administered in amounts sufficient to effect the differentiation of promyelocytes to normal macrophages. Dosages as described above are suitable, it being understood that the amounts given are to be adjusted in accordance with the severity of the disease, and the condition and response of the subject as is well understood in the art. If a solid carrier is used the dosage form of the compounds is typically tablets, capsules, powders, troches or lozenges. If a liquid carrier is used, soft gelatin capsules, or syrup or liquid suspensions, emulsions or solutions may be the dosage form.

Biological activity of 1α-Hydroxy-19-Nor-Vitamin D Compounds

The 19-nor compounds exhibit a pattern of biological activity having high potency in promoting the differentiation of malignant cells and little or no activity in calcifying bone tissue.

In this connection reference is made to the tests on differentiation of HL-60 cells and calcification activity for 1α,25-dihydroxy vitamin D_3 and its 19-nor analogu given in EP-A-387077.

It should be specifically noted that 1α-hydroxy-19-nor-vitamin D_3 is expected to be less active than 1α,25-dihydroxy-19-nor-vitamin D_3 in causing differentiation of HL60 cells in vitro. However, in vivo it is well established that 1α-hydroxy-vitamin D_3 is rapidly converted to 1α,25-dihydroxy-vitamin D_3, Hollick et al, Science, Vol. 190, pages 576-578 (1975) and Holick et al, Journal of Clinical Endocrinology & Metabolism, Vol. 44, pages 595-598 (1977). Thus, it is clear that the human body can rapidly convert the relatively inactive 1α-hydroxylated-19-nor-vitamin D compounds to metabolites highly active in causing cell differentiation. This in vivo capability makes possible the treatment of malignancies such as psoriasis with 1α-hydroxylated-19-nor-vitamin D compounds that do not initially have a hydroxyl group at the 24 or 25 carbon position in the side chain.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Use of a compound of formula I for the manufacture of a medicament for the treatment of psoriasis wherein formula I is:



I

where X and Y are each independently hydrogen, acyl alkylsilyl or alkoxyalkyl, and where U is selected from a side chain of the formula



wherein R_1 and R_2 are each independently alkyl, deuteroalkyl, hydroxyalkyl or fluoroalkyl, or, when taken together represent the group $-(CH_2)_m-$ where m is an integer having a value of from 2 to 5, R_3 is hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl or fluoroalkyl, R_6 is hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl or fluoroalkyl, or, R_3 and R_6 taken together represent double-bonded oxygen or double-bonded carbon, R_4 and R_5 taken together form a carbon-carbon triple bond, and wherein n is an integer having a value of from 1 to 5 and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom, with the proviso that when R_3 is other than hydroxy or O-acyl at least one of R_3 and R_6 is hydrogen or deuterium.

2. Use according to claim 1 wherein R_3 is hydroxy or O-acyl.

3. Use according to claim 1 or 2 wherein the medicament contains 0.01 μg to 100 μg of the compound per gram of the medicament.

4. Use according to any one of claims 1 to 3 wherein the medicament is administrable to a patient by oral or parenteral means, or by topical means when R_3 is hydroxy.

5. Use according to any one of the preceding claims wherein the medicament is used to provide an amount of the said compound of 0.1 μg/day to 100 μg/day.

6. A composition suitable for oral or parenteral treatment of psoriasis which comprises a compound of formula I as defined in claim 1 or 2 and an appropriate carrier.

7. A composition suitable for topical treatment of psoriasis which comprises a compound of formula I as defined in claim 1 where R_3 is hydroxy and an appropriate carrier.

8. A composition according to claim 6 or 7 which contains 0.01 μg to 100 μg of said compound per gram of the composition.

9. Use of a 1α-hydroxylated-19-nor-vitamin D compound of formula I as defined in claim 1 or 2 which compound upon administration to humans is converted to a metabolite and said metabolite in vitro will cause differentiation in a cell line for the manufacture of a medicament for the treatment of psoriasis.

10. Use according to claim 9 wherein said cell line is a U937 cell line, a HL60 cell line or a M1 cell line.

Claims for the following Contracting State : ES

1. A process for the manufacture of a medicament for the treatment of psoriasis which comprises mixing a compound of formula I



I

where X and Y are each independently hydrogen, acyl alkylsilyl or alkoxyalkyl, and where U is selected from a side chain of the formula.



wherein R_1 and R_2 are each independently alkyl, deuteroalkyl, hydroxyalkyl or fluoroalkyl, or, when taken together represent the group -- $(CH_2)_m$ -- where m is an integer having a value of from 2 to 5, R_3 is hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl or fluoroalkyl, R_6 is hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl or fluoroalkyl, or, R_3 and R_6 taken together represent double-bonded oxygen or double-bonded carbon, R_4 and R_5 taken together form a carbon-carbon triple bond, and wherein n is an integer having a value of from 1 to 5 and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom, with the proviso that when R_3 is other than hydroxy or O-acyl at least one of R_3 or R_6 is hydrogen or deuterium with an appropriate carrier.

2. A process according to claim 1 wherein R_3 is hydroxy or O-acyl.

3. A process according to claim 1 or 2 wherein the medicament contains 0.01 μg to 100 μg of the compound per gram of the medicament.

4. A process according to any one of claims 1 to 3 wherein the medicament is administrable to a patient by oral or parenteral means, or by topical means when R_3 is hydroxy.

5. Process according to any one of the preceding claims wherein the medicament is used to provide an amount of the said compound of 0.1 μg/day to 100 μg/day.

6. A process for the manufacture of a medicament for the treatment of psoriasis which comprises mixing a 1α-hydroxylated-19-nor-vitamin D compound of formula I as defined in claim 1 or 2 which compound upon administration to humans is converted to a metabolite and said metabolite in vitro will cause differentiation in a cell line, with an appropriate carrier.

Claims for the following Contracting State : GR

1. Use of a compound of formula I for th manufacture of a medicament for the treatment of psoriasis wherein formula I is:



I

where X and Y are each independently hydrogen, acyl alkylsilyl or alkoxyalkyl, and where U is selected from a side chain of the formula



wherein R_1 and R_2 are each independently alkyl, deuteroalkyl, hydroxyalkyl or fluoroalkyl, or, when taken together represent the group -- $(CH_2)_m$ -- where m is an integer having a value of from 2 to 5, R_3 is hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl or fluoroalkyl, R_6 is hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl or fluoroalkyl, or, R_3 and R_6 taken together represent double-bonded oxygen or double-bonded carbon, R_4 and R_5 taken together form a carbon-carbon triple bond, and wherein n is an integer having a value of from 1 to 5 and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom, with the proviso that when R_3 is other than hydroxy or O-acyl at least one of R_3 and R_6 is hydrogen or deuterium.

2. Use according to claim 1 wherein R_3 is hydroxy or 0-acyl.

3. Use according to claim 1 or 2 wherein the medicament contains 0.01 μg to 100 μg of the compound per gram of the medicament.

4. Use according to any one of claims 1 to 3 wherein the medicament is administrable to a patient by oral or parenteral means, or by topical means when R_3 is hydroxy.

5. Use according to any one of the preceding claims wherein the medicament is used to provide an amount of the said compound of 0.1 μg/day to 100 μg/day.

6. Use of a 1α-hydroxylated-19-nor-vitamin D compound of formula I as defined in claim 1 or 2 which compound upon administration to humans is converted to a metabolite and said metabolite in vitro will cause differentiation in a cell line for the manufacture of a medicament for the treatment of psoriasis.

7. Use according to claim 6 wherein said cell line is a U937 cell line, a HL60 cell line or a M1 cell line.

8. A process for preparing a composition suitable for oral or parenteral treatment of psoriasis which comprises a compound of formula I as defined in claim 1 or 2 and an appropriate carrier which comprises mixing the compound of formula I with the carrier.

9. A process for preparing a composition suitable for topical treatment of psoriasis which comprises a compound of formula I as defined in claim 1 where R_3 is hydroxy and an appropriate carrier which comprises mixing the compound of formula I with the carrier.

10. A process according to claim 8 or 9 in which the composition contains 0.01 µg to 100 µg of said compound per gram of the composition.

11. A process for the manufacture of a medicament for the treatment of psoriasis which comprises mixing a compound of formula I as defined in claim 1 with an appropriate carrier.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Verwendung einer Verbindung der Formel I zur Herstellung eines Medikaments zur Behandlung von Psoriasis



I

worin X und Y unabhängig voneinander Wasserstoff, Acyl, Alkylsilyl oder Alkoxyalkyl bedeuten, und U eine Seitenkette der Formel sind,



worin R_1 und R_2 unabhängig voneinander Alkyl, Deuteroalkyl, Hydroxyalkyl oder Fluoralkyl bedeuten, oder zusammen die Gruppe $-(CH_2)_m-$ bedeuten, worin m eine ganze Zahl von 2 bis 5 ist, R_3 Wasserstoff, Deuterium, Hydroxy, Fluor, O-Acyl, Alkyl, Hydroxyalkyl oder Fluoralkyl ist, R_6 Wasserstoff, Deuterium, Fluor, Alkyl, Hydroxyalkyl oder Fluoralkyl ist, oder R_3 und R_6 zusammen doppeltgebundenen Sauerstoff oder doppeltgebundenen Kohlenstoff bedeuten, R_4 und R_5 zusammen eine Kohlenstoff-Kohlenstoff-Dreifachbindung bilden, und n eine ganze Zahl von 1 bis 5 ist, und worin das Kohlenstoffatom in einer der Stellungen 20, 22 oder 23 in der Seitenkette durch ein O-, S- oder N-Atom ersetzt sein kann, mit der Maßgabe, daß, wenn R_3 von Hydroxy oder O-Acyl verschieden ist, mindestens einer der Reste R_3 und R_6 Wasserstoff oder Deuterium ist.

2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß R_3 Hydroxy oder O-Acyl ist.

3. Verwendung nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß das Arzneimittel 0,01 µg bis 100 µg der Verbindung pro Gramm Arzneimittel enthält.

4. Verwendung nach einen der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß das Arzneimittel an einen Patienten oral oder parenteral verabreichbar ist, oder, wenn R_3 Hydroxy ist, topisch.

5. Verwendung nach einen der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß das Arzneimittel so verwendet wird, daß die Verbindung in einer Menge von 0,1 µg/Tag bis 100 µg/Tag bereitgestellt wird.

6. Zusammensetzung zur oralen oder parenteralen Behandlung von Psoriasis, dadurch gekennzeichnet, daß sie eine Verbindung der Formel I nach Anspruch 1 oder 2 und einen geeigneten Träger umfaßt.

7. Zusammensetzung zur topischen Behandlung von Psoriasis, dadurch gekennzeichnet, daß sie eine Verbindung der Formel I nach Anspruch 1, worin R_3 Hydroxy ist, und einen geeigneten Träger umfaßt.

8. Zusammensetzung nach Anspruch 6 oder 7, dadurch gekennzeichnet, daß sie 0,01 µg bis 100 µg der Verbindung pro Gramm der Zusammensetzung enthält.

9. Verwendung einer 1α-hydroxylierten 19-Norvitamin D-Verbindung der Formel I nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß die Verbindung bei der Verabreichung an Menschen in einen Metaboliten überführt wird, und der Metabolit in vitro eine Differenzierung einer Zellinie zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis verursacht.

10. Verwendung nach Anspruch 9, dadurch gekennzeichnet, daß die Zellinie eine U937-Zellinie, eine HL60-Zellinie oder eine M1-Zellinie ist.

Patentansprüche für folgenden Vertragsstaat : ES

1. Verfahren zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis, dadurch gekennzeichnet, daß man eine Verbindung der Formel I



I

worin X und Y unabhängig voneinander Wasserstoff, Acyl, Alkylsilyl oder Alkoxyalkyl bedeuten, und U eine Seitenkette der Formel sind,



worin R_1 und R_2 unabhängig voneinander Alkyl, Deuteroalkyl, Hydroxyalkyl oder Fluoralkyl bedeuten, oder zusam-

men die Gruppe -$(CH_2)_m$- bedeuten, worin m eine ganze Zahl von 2 bis 5 ist, R_3 Wasserstoff, Deuterium, Hydroxy, Fluor, O-Acyl, Alkyl, Hydroxyalkyl oder Fluoralkyl ist, R_6 Wasserstoff, Deuterium, Fluor, Alkyl, Hydroxyalkyl oder Fluoralkyl ist, oder R_3 und R_6 zusammen doppeltgebundenen Sauerstoff oder doppeltgebundenen Kohlenstoff bedeuten, R_4 und R_5 zusammen eine Kohlenstoff-Kohlenstoff-Dreifachbindung bilden, und n eine ganze Zahl von 1 bis 5 ist, und worin das Kohlenstoffatom in einer der Stellungen 20, 22 oder 23 in der Seitenkette durch ein O-, S- oder N-Atom ersetzt sein kann, mit der Maßgabe, daß, wenn R_3 von Hydroxy oder O-Acyl verschieden ist, mindestens einer der Reste R_3 und R_6 Wasserstoff oder Deuterium ist, mit einem geeigneten Träger mischt.

2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß R_3 Hydroxy oder O-Acyl ist.

3. Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß das Arzneimittel 0,01 µg bis 100 µg der Verbindung pro Gramm Arzneimittel enthält.

4. Verfahren nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß das Arzneimittel an einen Patienten oral oder parenteral verabreichbar ist, oder, wenn R_3 Hydroxy ist, topisch.

5. Verfahren nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß das Arzneimittel so verwendet wird, daß die Verbindung in einer Menge von 0,1 µg/Tag bis 100 µg/Tag bereitgestellt wird.

6. Verfahren zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis, dadurch gekennzeichnet, daß man eine 1α-hydroxylierte 19-Norvitamin D-Verbindung der Formel I nach Anspruch 1 oder 2, die bei der Verabreichung an Menschen in einen Metaboliten übergeführt wird, und der Metabolit in vitro die Differenzierung einer Zellinie verursacht, mit einen geeigneten Träger mischt.

Patentansprüche für folgenden Vertragsstaat : GR

1. Verwendung einer Verbindung der Formel I zur Herstellung eines Medikaments zur Behandlung von Psoriasis



I

worin X und Y unabhängig voneinander Wasserstoff, Acyl, Alkylsilyl oder Alkoxyalkyl bedeuten, und U eine Seitenkette der Formel sind,



worin R_1 und R_2 unabhängig voneinander Alkyl, Deuteroalkyl, Hydroxyalkyl oder Fluoralkyl bedeuten, oder zusam-

men die Gruppe $-(CH_2)_m-$ bedeuten, w rin m eine ganze Zahl von 2 bis 5 ist, R_3 Wasserstoff, Deuterium, Hydroxy, Fluor, O-Acyl, Alkyl, Hydroxyalkyl oder Fluoralkyl ist, R_6 Wasserstoff, Deuterium, Fluor, Alkyl, Hydroxyalkyl oder Fluoralkyl ist, oder R_3 und R_6 zusammen doppeltgebundenen Sauerstoff oder doppeltgebundenen Kohlenstoff bedeuten, R_4 und R_5 zusammen eine Kohlenstoff-Kohlenstoff-Dreifachbindung bilden, und n eine ganze Zahl von 1 bis 5 ist, und worin das Kohlenstoffat m in einer der Stellungen 20, 22 oder 23 in der Seitenkette durch ein O-, S- oder N-Atom ersetzt sein kann, mit der Maßgabe, daß, wenn R_3 von Hydroxy oder O-Acyl verschieden ist, mindestens einer der Reste R_3 und R_6 Wasserstoff oder Deuterium ist.

2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß R_3 Hydroxy oder O-Acyl ist.

3. Verwendung nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß das Arzneimittel 0,01 µg bis 100 µg der Verbindung pro Gramm Arzneimittel enthält.

4. Verwendung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß das Arzneimittel an einen Patienten oral oder parenteral verabreichbar ist, oder, wenn R_3 Hydroxy ist, topisch.

5. Verwendung nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, daß das Arzneimittel so verwendet wird, daß die Verbindung in einer Menge von 0,1 µg/Tag bis 100 µg/Tag bereitgestellt wird.

6. Verwendung einer 1α-hydroxylierten 19-Norvitamin D-Verbindung der Formel I nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß die Verbindung bei der Verabreichung an Menschen in einen Metaboliten überführt wird, und der Metabolit in vitro eine Differenzierung einer Zellinie zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis verursacht.

7. Verwendung nach Anspruch 6, dadurch gekennzeichnet, daß die Zellinie eine U937-Zellinie, eine HL60-Zellinie oder eine M1-Zellinie ist.

8. Verfahren zur Herstellung einer zur oralen oder parenteralen Behandlung von Psoriasis geeigneten Zusammensetzung, die eine Verbindung der Formel I nach Anspruch 1 oder 2 und einen geeigneten Träger umfaßt, dadurch gekennzeichnet, daß man die Verbindung der Formel I mit dem Träger mischt.

9. Verfahren zur Herstellung einer zur topischen Behandlung von Psoriasis geeigneten Zusammensetzung, die eine Verbindung der Formel I nach Anspruch 1, worin R_3 Hydroxy ist, und einen geeigneten Träger umfaßt, dadurch gekennzeichnet, daß man die Verbindung der Formel I mit dem Träger mischt.

10. Verfahren nach Anspruch 8 oder 9, dadurch gekennzeichnet, daß die Zusammensetzung 0,01 µg bis 100 µg der Verbindung pro Gramm der Zusammensetzung enthält.

11. Verfahren zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis, dadurch gekennzeichnet, daß man eine Verbindung der Formel I nach Anspruch 1 mit einem geeigneten Träger mischt.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Utilisation d'un composé de formule I pour la fabrication d'un médicament destiné au traitement du psoriasis, la formule I étant la suivante :



I

dans laquelle X et Y représentent chacun, indépendamment, un atome d'hydrogène ou un groupe acyle, alkylsilyle ou alcoxyalkyle, et U représente une chaîne latérale de formule



dans laquelle R_1 et R_2 représentent chacun, indépendamment, un groupe alkyle, deutéroalkyle, hydroxyalkyle ou fluoroalkyle, ou bien représentent conjointement un groupe $—(CH_2)_m—$ où m représente un nombre entier valant de 2 à 5, R_3 représente un atome d'hydrogène, de deutérium ou de fluor ou un groupe hydroxyle, O-acyle, alkyle, hydroxyalkyle ou fluoroalkyle, R_6 représente un atome d'hydrogène, de deutérium ou de fluor ou un groupe alkyle, hydroxyalkyle ou fluoroalkyle, ou bien R_3 et R_6 représentent conjointement un atome d'oxygène a double liaison ou un atome de carbone à double liaison, R_4 et R_5 représentent conjointement une triple liaison carbone-carbone et n représente un nombre entier valant de 1 à 5, et l'atome de carbone occupant n'importe laquelle des positions 20, 22 et 23 dans la chaîne latérale peut être remplacé par un atome d'oxygène, de soufre ou d'azote, sous réserve que, si R_3 représente autre chose qu'un groupe hydroxyle ou O-acyle, au moins l'un des R_3 et R_6 représente un atome d'hydrogène ou de deutérium.

2. Utilisation conforme à la revendication 1, pour laquelle R_3 représente un groupe hydroxyle ou O-acyle.

3. Utilisation conforme à la revendication 1 ou 2, où le médicament contient de 0,01 µg à 100 µg du composé par gramme de médicament.

4. Utilisation conforme à l'une des revendications 1 à 3, où le médicament peut être administré à un patient par voie orale ou parentérale, ou encore en usage externe si R_3 représente un groupe hydroxyle.

5. Utilisation conforme à l'une des revendications précédentes, où l'on emploie le médicament de façon à apporter ledit composé en une quantité de 0,1 µg/jour à 100 µg/jour.

6. Composition appropriée pour le traitement du psoriasis par voie orale ou parentérale, qui contient un composé de formule I, définie dans la revendication 1 ou 2, et un véhicule convenable.

7. Composition appropriée, en usage externe, pour le traitement du psoriasis, qui contient un composé de formule I, définie dans la revendication 1, où R_3 représente un groupe hydroxyle, et un véhicule convenable.

8. Composition conforme à la revendication 6 ou 7, qui contient de 0,01 µg à 100 µg dudit composé par gramme de

composition.

9. Utilisation d'une 1α-hydroxy-19-nor-vitamine D, composé de formule I définie dans la revendication 1 ou 2, lequel composé est converti, après administration chez l'homme, en un métabolite qui provoque in vitro la différenciation d'une lignée cellulaire, pour la fabrication d'un médicament destiné au traitement du psoriasis.

10. Utilisation conforme à la revendication 9, ladite lignée cellulaire étant une lignée de cellules U937, une lignée de cellules HL60 ou une lignée de cellules M1.

Revendications pour l'Etat contractant suivant : ES

1. Procédé de fabrication d'un médicament destiné au traitement du psoriasis, qui comporte le fait de mélanger avec un véhicule approprié un composé de formule I :



I

dans laquelle X et Y représentent chacun, indépendamment, un atome d'hydrogène ou un groupe acyle, alkylsilyle ou alcoxyalkyle, et U représente une chaîne latérale de formule



dans laquelle R_1 et R_2 représentent chacun, indépendamment, un groupe alkyle, deutéroalkyle, hydroxyalkyle ou fluoroalkyle, ou bien représentent conjointement un groupe $-(CH_2)_m-$ où m représente un nombre entier valant de 2 à 5, R_3 représente un atome d'hydrogène, de deutérium ou de fluor ou un groupe hydroxyle, O-acyle, alkyle, hydroxyalkyle ou fluoroalkyle, R_6 représente un atome d'hydrogène, de deutérium ou de fluor ou un groupe alkyle, hydroxyalkyle ou fluoroalkyle, ou bien R_3 et R_6 représentent conjointement un atome d'oxygène à double liaison ou un atome de carbone à double liaison, R_4 et R_5 représentent conjointement une triple liaison carbone-carbone et n représente un nombre entier valant de 1 à 5, et l'atome de carbone occupant n'importe laquelle des positions 20, 22 et 23 dans la chaîne latérale peut être remplacé par un atome d'oxygène, de soufre ou d'azote, sous réserve que, si R_3 représente autre chose qu'un groupe hydroxyle ou O-acyle, au moins l'un des R_3 et R_6 représente un atome d'hydrogène ou de deutérium.

2. Procédé conforme à la revendication 1, dans lequel R_3 représente un groupe hydroxyle ou O-acyle.

3. Procédé conforme à la revendication 1 ou 2, dans lequel le médicament contient de 0,01 µg à 100 µg du composé par gramme de médicament.

4. Procédé conforme à l'une des revendications 1 à 3, où le médicament peut être administré à un patient par voie orale ou parentérale, ou encore en usage externe si R_3 représente un groupe hydroxyle.

5. Procédé conforme à l'une des revendications précédentes, où l'on emploie le médicament de façon à apporter ledit composé en une quantité de 0,1 µg/jour à 100 µg/jour.

6. Procédé de fabrication d'un médicament destiné au traitement du psoriasis, qui comporte le fait de mélanger avec un véhicule approprié une 1α-hydroxy-19-nor-vitamine D, composé de formule I définie dans la revendication 1 ou 2, lequel composé est converti, après administration chez l'homme, en un métabolite qui provoque in vitro la différenciation d'une lignée cellulaire.

Revendications pour l'Etat contractant suivant : GR

1. Utilisation d'un composé de formule I pour la fabrication d'un médicament destiné au traitement du psoriasis, la formule I étant la suivante :



I

dans laquelle X et Y représentent chacun, indépendamment, un atome d'hydrogène ou un groupe acyle, alkylsilyle ou alcoxyalkyle, et U représente une chaîne latérale de formule



dans laquelle R_1 et R_2 représentent chacun, indépendamment, un groupe alkyle, deutéroalkyle, hydroxyalkyle ou fluoroalkyle, ou bien représentent conjointement un groupe $-(CH_2)_m-$ où m représente un nombre entier valant de 2 à 5, R_3 représente un atome d'hydrogène, de deutérium ou de fluor ou un groupe hydroxyle, O-acyle, alkyle, hydroxyalkyle ou fluoroalkyle, R_6 représente un atome d'hydrogène, de deutérium ou de fluor ou un groupe alkyle, hydroxyalkyle ou fluoroalkyle, ou bien R_3 et R_6 représentent conjointement un atome d'oxygène à double liaison ou un atome de carbone à double liaison, R_4 et R_5 représentent conjointement une triple liaison carbone-carbone et n représente un nombre entier valant de 1 à 5, et l'atome de carbone occupant n'importe laquelle des positions 20, 22 et 23 dans la chaîne latérale peut être remplacé par un atome d'oxygène, de soufre ou d'azote, sous réserve que, si R_3 représente autre chose qu'un groupe hydroxyle ou O-acyle, au moins l'un des R_3 et R_6 représente un atome d'hydrogène ou de deutérium.

2. Utilisation conforme à la revendication 1, pour laquelle R_3 représente un groupe hydroxyle ou O-acyle.

3. Utilisation conforme à la revendication 1 ou 2, où le médicament contient de 0,01 µg à 100 µg du composé par

gramme de médicament.

4. Utilisation conforme à l'une des revendications 1 à 3, où le médicament peut être administré à un patient par voie orale ou parentérale, ou encore en usage externe si R_3 représente un groupe hydroxyle.

5. Utilisation conforme à l'une des revendications précédentes, où l'on emploie le médicament de façon à apporter ledit composé en une quantité de 0,1 µg/jour à 100 µg/jour.

6. Utilisation d'une 1α-hydroxy-19-nor-vitamine D, composé de formule I définie dans la revendication 1 ou 2, lequel composé est converti, après administration chez l'homme, en un métabolite qui provoque in vitro la différenciation d'une lignée cellulaire, pour la fabrication d'un médicament destiné au traitement du psoriasis.

7. Utilisation conforme à la revendication 6, ladite lignée cellulaire étant une lignée de cellules U937, une lignée de cellules HL60 ou une lignée de cellules M1.

8. Procédé de préparation d'une composition appropriée pour le traitement du psoriasis par voie orale ou parentérale, qui contient un composé de formule I, définie dans la revendication 1 ou 2, et un véhicule convenable, lequel procédé comporte le fait de mélanger le composé de formule I avec le véhicule.

9. Procédé de préparation d'une composition appropriée, en usage externe, pour le traitement du psoriasis, qui contient un composé de formule I, définie dans la revendication 1, où R_3 représente un groupe hydroxyle, et un véhicule convenable, lequel procédé comporte le fait de mélanger le composé de formule I avec le véhicule.

10. Procédé conforme à la revendication 8 ou 9, dans lequel la composition contient de 0,01 µg à 100 µg dudit composé par gramme de composition.

11. Procédé de fabrication d'un médicament destiné au traitement du psoriasis, qui comporte le fait de mélanger un composé de formule I, définie dans la revendication 1, avec un véhicule approprié.

(19) Europäis hes Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: 0 474 517 A2

(12) # EUROPEAN PATENT APPLICATION

(21) Application number: 91308205.3

(51) Int. Cl.[5]: A61K 31/59

(22) Date of filing: 09.09.91

(30) Priority: 07.09.90 US 579935

(43) Date of publication of application:
11.03.92 Bulletin 92/11

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
614 North Walnut Street
Madison, WI 53705 (US)

(72) Inventor: DeLuca, Hector Floyd
1809 Highway BB
Deerfield, Wisconsin 53531 (US)

(74) Representative: Ellis-Jones, Patrick George Armine et al
J.A. KEMP & CO. 14 South Square Gray's Inn
London WC1R 5LX (GB)

(54) **Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis.**

(57) A novel use for 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis inasmuch as these compounds when administered to humans are converted to a metabolite, such as a 1α,25-dihydroxylated compound, which metabolite in vitro will cause differentiation in a human cell line.

EP 0 474 517 A2

Ba kground of the Invention

Th present invention relates t vitamin D compounds, and more particularly t the use f 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis.

The D vitamins are very important agents for the control of calcium and phosphate metabolism in animals and humans, and have long been used as dietary supplements and in clinical practice to assure proper bone growth and development. It is now known that the in vivo activity of these vitamins, specifically of vitamin D_2 and D_3, is dependent on metabolism to hydroxylated forms. Thus, vitamin D_3 undergoes two successive hydroxylation reactions in vivo, leading first to 25-hydroxyvitamin D_3 and then to 1,25-dihydroxyvitamin D_3 and the latter is indeed thought to be the compound responsible for the well-known beneficial effects of vitamin D_3. Likewise, vitamin D_2, which is commonly used as a dietary supplement, undergoes an analogous hydroxylation sequence to its active forms, being first converted to 25-hydroxyvitamin D_2 (25-OH-D_2) and then to 1,25-dihydroxyvitamin D_2 (1,25-$(OH)_2D_2$). These facts are well established and well known in the art (see, for example, Suda et al. Biochemistry 8, 3515 (1969) and Jones et al. Biochemistry 14, 1250 (1975)).

Hollick, U. S. Patent No. 4,728,643 discloses a method of treating psoriasis with vitamin D compounds which in vitro cause cell differentiation. However 1α-hydroxylated vitamin D compounds, i.e. those compounds having only a hydroxyl group at the carbon 1 position and initially lacking a hydroxyl group at the carbon 24 or 25 positions, are relatively inactive in causing cell differentiation in vitro. Additionally, it is also well known that 1α-hydroxylated compounds are rapidly converted in vivo to 1α,25-dihydroxy compounds, e.g. 1α-hydroxyvitamin D_3 to 1α,25-dihydroxy-vitamin D_3, or if the 25 carbon position is blocked to 1α,24-dihydroxy compounds. Hollick et al, Science, Vol. 190, pages 576-578 (1975) and Hollick et al, J. of Clinical Endocrinology & Metabolism, Vol. 44, pages 595-598 (1977). For example, in PCT patent application number PCT/DK89/00079 filed April 7, 1989 and published November 2, 1989 under number WO89/10351 there is disclosed numerous side chain homologated vitamin D compounds lacking the hydroxyl group at the carbon 25 position in the side chain. It is disclosed therein that such compounds are converted in vivo to active compounds having a hydroxyl group at the carbon 25 position by enzymatic hydroxylation, and may thus be used for the treatment of psoriasis. Thus, the human body can rapidly convert relatively inactive 1α-hydroxylated vitamin D compounds to metabolites highly active in causing cell differentiation. There has, however, been a failure in the art to recognize the ability of 1α-hydroxylated-19-nor-vitamin D compounds to treat malignancies such as psoriasis.

Summary of the Invention

Compositions containing one or more 1α-hydroxylated-19-nor-vitamin D compounds which compounds when administered to humans are converted to a metabolite, which metabolite in vitro has cell differentiation activity, together with a suitable carrier useful in the treatment of psoriasis are described. The treatment may be topical, oral or parenteral. Methods of employing the compositions are also disclosed. The compounds are present in the composition in an amount from about 0.01 μg/gm to about 100 μg/gm of the composition, and may be administered orally or parenterally in dosages of from about 0.01 μg/day to about 100 μg/day.

The compounds disclosed herein unexpectedly provide highly effective treatments for psoriasis without producing unwanted systemic or local side effects.

Detailed Description of the Invention

The vitamin D compounds useful in the compositions of the present invention and for the treatment of psoriasis and other malignancies are those which are solely 1α-hydroxylated, i.e. those that do not initially have a hydroxyl group at the 24 or 25 carbon position in the side chain. Such 1α-hydroxylated compounds are readily converted to 1α,25-dihydroxy or 1α,24-dihydroxy compounds in vivo. These dihydroxy compounds are highly potent in inducing cellular differentiation, and the preferred compounds are those which induce cellular differentiation with minimal or no effect on either intestinal calcium absorption or bone calcium mobilization. Accordingly, specific preferred examples of vitamin D compounds defined by the above functions are those selected from the group consisting of 1α-hydroxy-19-nor-vitamin D compounds.

The 1α-19-nor-vitamin D compounds referred to herein are a class of 1α-hydroxylated vitamin D compounds in which the ring A exocyclic methylene group (carbon 19) typical of all vitamin D systems has been removed and replaced by two hydrogen atoms. Structurally these novel analogs are characterized by the general formula II shown below:



II

where X and Y are each selected from the group consisting of hydrogen, acyl, alkylsilyl and alkoxyalkyl, and where the group U represents any of the typical side chains known for vitamin D compounds that are not hydroxylated at the carbon 25 position in the side chain. Thus, U may represent the following side chain:



wherein R_1 and R_2 are each selected from the group consisting of alkyl, hydroxyalkyl and fluoroalkyl, deuteroalkyl or, when taken together represent the group -- $(CH_2)_m$ -- where m is an integer having a value of from 2 to 5, R_3 is selected from the group consisting of hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl and fluoroalkyl, R_6 is selected from the group consisting of hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl and fluoroalkyl, or, R_3 and R_6 taken together represent double-bonded oxygen or double-bonded carbon, R_4 and R_5 are each selected from the group consisting of hydrogen, deuterium, hydroxy, O-acyl, fluorine and alkyl, or, R_4 and R_6 taken together form a carbon-carbon double bond or a carbon-carbon triple bond, and wherein n is an integer having a value of from 1 to 5, and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom.

Specific important examples of side chains for the 19-nor compounds are the structures represented by formulas (a), (b), (c), (d) and (e) below, i.e. the side chain as it occurs in 25-hydroxyvitamin D_3 (a); vitamin D_3 (b); 25-hydroxyvitamin D_2 (c); vitamin D_2 (d); and the C-24-epimer of 25-hydroxyvitamin D_2 (e).



It should be noted that structures (a), (c) and (e) shown above are examples of three 19-nor compounds after each has been metabolized in vivo to 1,25-dihydroxy compounds.

As used in the description, and in the claims, the term "hydroxy-protecting group" refers to any group commonly used for the protection of hydroxy functions during subsequent reactions, including, for example, acyl or alkylsilyl groups such as trimethylsilyl, triethylsilyl, t-butyldimethylsilyl and analogous alkylated silyl radicals, or alkoxyalkyl groups such as methoxymethyl, ethoxymethyl, methoxyethoxymethyl, tetrahydrofuranyl or tetrahydropyranyl. A "protected-hydroxy" is a hydroxy function derivatized by one of the above hydroxy-protecting groupings. "Alkyl" represents a straight-chain or branched hydrocarbon radical of 1 to 10 carbons in all its isomeric forms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, etc., and the terms "hydroxyalkyl", "fluoroalkyl" and "duteroalkyl" refer to such an alkyl radical substituted by one or more hydroxy or fluoro or deuterium groups respectively. An acyl group is an alkanoyl group of 1 to 6 carbons in all its isomeric forms, or an aroyl group, such as benzoyl, or halo-, nitro- or alkyl-substituted benzoyl groups, or a dicarboxylic acyl group such as oxalyl, malonyl, succinoyl, glutaroyl, or adipoyl. The term "aryl" signifies a phenyl-, or an alkyl-, nitro- or halo-substituted phenyl group.

It should be noted in this description that the term "24-dihomo" refers to the addition of two methylene groups at the carbon 24 position in the side chain. Likewise, the term "trihomo" refers to the addition of three methylene groups. Also, the term "26,27-dimethyl" refers to the addition of a methyl group at the carbon 26 and 27 positions so that for example R_1 and R_2 are ethyl groups. Likewise, the term "26,27-diethyl" refers to the addition of an ethyl group at the 26 and 27 positions so that R_1 and R_2 are propyl groups.

Specific and preferred examples of these 1α-hydroxylated compounds when the side chain is unsaturated (i.e. R_4 and R_5 represent a double bond) are: 24-dihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound shown above, where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each a methyl group; 26,27-dimethyl-24-dihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each an ethyl group; 24-trihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound having the structure shown above, where X and Y are hydrogen, n equals 4, and R_1 and R_2 are each a methyl group; 26,27-dimethyl-24-trihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 4, and R_1 and R_2 are each an ethyl group; 26,27-diethyl-24-dihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each a propyl group; 26,27-diethyl-24-trihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 4, and R_1 and R_2 are each a propyl group, 26,27-dipropyl-24-dihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each a butyl group; and 26,27-dipropyl-24-trihomo-1α-hydroxy-19-nor-22-dehydrovitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 4, and R_1 and R_2 are each a butyl group.

Specific and preferred examples of these compounds when the side chain is saturated (i.e. R_4 and R_5 each represent hydrogen) are: 24-dihomo-1α-hydroxy-19-nor-vitamin D_3, i.e. the compound shown above, where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each a methyl group; 26,27-dimethyl-24-dihomo-1α-hydroxy-19-nor-vitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each an ethyl group; 24-trihomo-1α-hydroxy-19-nor-vitamin D_3, i.e. the compound having th structure shown above, where X and Y are hydrogen, n equals 4, and R_1 and R_2 are each a methyl group; 26,27-dime-

thyl-24-trihomo-1α-hydroxy-19-nor-vitamin D_3, the compound shown above where X and Y are hydrogen, n equals 4, and R_1 and R_2 are each an ethyl group; 26,27-diethyl-24-dihomo-1α-hydroxy-19-nor-vitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each a propyl group; 26, 27-diethyl-24-trihomo-1α-hydroxy-19-nor-vitamin D_3, i.e. the compound shown abov wh re X and Y are hydrogen, n equals 4, and R_1 and R_2 are each a propyl group; 26,27-dipropyl-24-dihomo-1α-hydroxy-19-nor-vitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 3, and R_1 and R_2 are each a butyl group; and 26,27-dipropyl-24-trihomo-1α-hydroxy-19-nor-vitamin D_3, i.e. the compound shown above where X and Y are hydrogen, n equals 4, and R_1 and R_2 are each a butyl group.

The preparation of 1α-hydroxy-19-nor-vitamin D compounds having the basic structure shown above in formula II can be accomplished by a common general method, using known vitamin D compounds as starting materials. Suitable starting materials are, for example, the vitamin D compounds of the general structure IV:



IV

where U is any of the side chains as defined above. These vitamin D starting materials are known compounds, or compounds that can be prepared by known methods.

Using the procedure of DeLuca et al U.S. Patent 4,195,027, the starting material is converted to the corresponding 1α-hydroxy-3,5-cyclovitamin D derivative, having the general structure V below, where X^3 represents hydrogen and Q represents an alkyl, preferably methyl:



V

So as to preclude undesired reaction of the 1α-hydroxy group in subsequent steps, the hydroxy group is converted to the corresponding acyl derivative, i.e. the compound V shown above, where X^3 represents an acyl group, using standard acylation procedures, such as treatment with an acyl anhydride or acyl halide in pyridine at room temperature or slightly elevated temperature (30-70°C). It should be understood also that whereas the process of this invention is illustrated here with acyl protection of hydroxy functions, alternative standard hydroxy-protecting groups can also be used, such as, for example, alkylsilyl or alkoxyalkyl groups. Such protecting groups are well-known in the art (e.g. trimethylsilyl, triethylsilyl, t.-butyldimethylsilyl, or tetrahydrofuranyl, methoxymethyl), and their use is considered a routine modification of experimental detail within the scope of the process of this invention.

The d rivative as obtained above is then reacted with osmium tetroxide, to produce the 10,19-dihydroxy analog, VI (where X^3 is acyl), which is subject d to diol cleavage using sodium metaperiodate or similar vicinal

diol cleavage reag nts (e.g. lead tetraac tate) to obtain the 10-oxo-intermediate, having the structure VII b low (where X^3 is acyl):



VI



VII

These two consecutive steps can be carried out according to the procedures given by Paaren et al. (J. Org. Chem. 48, 3819 (1983)). If the side chain unit, U carries vicinal diols (e.g. 24,25-dihydroxy- or 25,26-dihydroxy, etc.), these, of course, also need to be protected, e.g. via acylation, silylation, or as the isopropylidene derivative prior to the periodate cleavage reactions.

In most cases, the acylation of the 1α-hydroxy group as mentioned above will simultaneously effect the acylation of side chain hydroxy functions, and these acylation conditions can, of course, be appropriately adjusted (e.g. elevated temperatures, longer reaction times) so as to assure complete protection of side chain vicinal diol groupings.

The next step of the process comprises the reduction of the 10-oxo-group to the corresponding 10-alcohol having the structure VIII shown below (where X^3 is acyl and Y^3 represents hydroxy). When X^3 is acyl, this reduction is carried out conveniently in an organic solvent at from about 0°C to about room temperature, using $NaBH_4$ or equivalent hydride reducing agents, selective for the reduction of carbonyl groups without cleaving ester functions. Obviously, when X^3 is a hydroxy-protecting group that is stable to reducing agents, any of the other hydride reducing agents (e.g. $LiAlH_4$, or analogous reagents) may be employed also.



VIII

The 10-hydroxy intermediate is then treated with an alkyl-or arylsulfonylhalide (e.g. methanesulfonylchloride) in a suitable solvent (e.g. pyridine) to obtain the corresponding 10-0-alkyl-or arylsulfonyl derivative (the compound having the structure shown VIII above, where Y^3 is alkyl-SO_2O-, or aryl-SO_2O-, and this sulfonate int rmediate is then directly reduced, with lithium aluminum hydride, or the analogous known lithium aluminum alkyl hydride reagents in an ther solvent, at a temperature ranging from 0°C to th boiling temperature f the solvent, thereby displacing the sulfonate group and obtaining the 10-deoxy derivative, represent d by the structure VIII abov , where X^3 and Y^3 are both hydrogen. As shown by the above structure, a 1-0-acyl

function in the precursor compound VII is also cleaved in this reduction step t produce th free 1α-hydroxy function, and any 0-acyl protecting group in the side chain would, of cours , likewise be reduced t th corresponding free alcohol function, as is well understood in the art. If desired, th hydroxy groups at C-1 (r hydroxy groups in the side chain) can be reprotect d by acylation or silylation or ether formation to the corresp nding acyl, alkylsilyl or alkoxyalkyl derivativ , but such protection is not required. Alt rnativ hydroxy-pr t cting groups, such as alkylsilyl or alkoxyalkyl groups would be retained in this reduction step, but can be removed, as desired, at this or later stages in the process by standard methods known in the art.

The above 1α-hydroxy-10-deoxy cyclovitamin D intermediate is next solvolyzed in the presence of a low-molecular weight organic acid, using the conditions of DeLuca et al U.S. Patents 4,195,027 and 4,260,549. When the solvolysis is carried out in acetic acid, for example, there is obtained a mixture of 1α-hydroxy-19-nor-vitamin D 3-acetate and 1α-hydroxy-19-nor-vitamin D 1-acetate (compounds IX and X, below), and the analogous 1- and 3-acylates are produced, when alternative acids are used for solvolysis.



IX



X

Direct basic hydrolysis of this mixture under standard conditions then produces the desired 1α-hydroxy-19-nor-vitamin D compounds of structure II above (where X^1 and Y^1 are both hydrogen). Alternatively, the above mixture of monoacetates may also be separated (e.g. by high pressure liquid chromatography) and the resulting 1-acetate and 3-acetate isomers may be subjected separately to hydroxysis to obtain the same final product from each, namely the 1α-hydroxy-19-nor-vitamin D compounds of structure II. Also the separated monoacetates of structure IX or X or the free 1,3-dihydroxy compound can, of course, be reacylated according to standard procedures with any desired acyl group, so as to produce the product of structure II above, where X^1 and Y^1 represent acyl groups which may be the same or different.

The 19-nor-vitamin D compounds useful in this invention are more specifically described by the following illustrative examples. In these examples specific products identified by Roman numerals and letters, i.e. IIa, IIb, ..., etc. refer to the specific structures and side chain combinations identified in the preceding description.

Example 1

Preparation of 1α,25-dihydroxy-19-nor-vitamin D_3 (IIa)

(a) 1α, 25-Dihydroxy-3,5-cyclovitamin D_3 1-acetate, 6-methyl ether: Using 25-hydroxyvitamin D_3 (IVa) as starting material, the known 1α,25-dihydroxy-3,5-cyclovitamin derivative Va (X^3=H) was prepared according to published procedures (DeLuca et al., U. S. Patent 4,195,027 and Paaren et al., J. Org. Chem. 45, 3252 (1980)). This product was then acylated under standard conditions to obtain the corresponding 1-acetate derivative Va (X^3=Ac).

(b) 10,19-Dihydro-1α,10,19,25-tetrahydroxy-3,5-cyclovitamin $D_3$1-acetate, 6-methyl ether (VIa): Intermediate Va (X^3=Ac) was treated with a slight molar excess of osmium tetroxide in pyridine according to the general procedure described by Paaren et al. (J. Org. Chem. 48, 3819 (1983)) to obtain the 10,19-dihydroxylated derivative VIa. Mass spectrum m/z (relative intensity), 506 (M^+, 1), 488 (2), 474 (40), 425 (45), 396 (15), 285 (5), 229 (30), 133 (45), 59 (80), 43 (100). ^{1}H, NMR ($CDCl_3$) δ 0.52 (3H, s, 18-CH_3, 0.58 (1H, m, 3-H), 0.93 (3H, d, J=6.1 Hz, 21-CH_3, 1.22 (6H, s, 26-CH_3 and 27-CH_3), 2.10 (3H, s, $COCH_3$), 3.25 (3H, s, 6-OCH_3 3.63 (2H, m, 19-CH_2), 4.60 (1H, d, J=9.2 Hz, 6-H), 4.63 (1H, dd, 1β-H), 4.78 (1H, d, J=9.2 Hz, 7-H).

(c) 1α,25-Dihydroxy-10-oxo-3,5-cyclo-19-nor-vitamin D_3 1-acetate, 6-methyl ether (VIIa): The 10,19-dihydroxylated intermediate VIa was treated with a solution of sodium metaperi date according to the procedure given by Paaren et al. (J. Org. Chem. 48, 3819, 1983) to produce the 10-oxo-cyclovitamin D derivative (VIIa, X^3=Ac). Mass spectrum m/z (r lative intensity) 442 (M^+-MeOH) (18), 424 (8), 382 (15), 364 (35), 253 (55), 225 (25), 197 (53), 155 (85), 137 (100). ^{1}H NMR ($CDCl_3$) δ 0.58 (3H, s, 18-CH_3), 0.93 (3H, d, J=6.6 Hz, 21-CH_3), 1.22 (6H, s, 26-CH_3 and 27-CH_3), 2.15 (s, 3-$OCOCH_3$), 3.30 (3H, s, 6-OCH_3), 4.61 (1H, d, J=9.1 Hz, 6-H), 4.71 (1H, d, J=9.6 Hz, 7-H), 5.18 (1H,m, 1β-H).

It has been found also that this diol cleavage reaction does not require elevated temperatures, and it is, indeed, generally preferable to conduct the reaction at approximately room temperature.

(d) 1α-Acetoxy-10,25-dihydroxy-3,5-cyclo-19-nor-vitamin D_3 6-methyl ether (VIIIa, X^3=Ac, Y^3=OH): The 10-oxo derivative VIIa (X^3=Ac) (2.2 mg, 4.6 µmol) was dissolved in 0.5 ml of ethanol and to this solution 50 µl (5.3 µmol) of a $NaBH_4$ solution (prepared from 20 mg of $NaBH_4$, 4.5 ml water and 0.5 ml of 0.01 N NaOH solution) was added and the mixture stirred at 0°C for ca. 1.5 h, and then kept at 0°C for 16 h. To the mixture ether was added and the organic phase washed with brine, dried over $MgSO_4$, filtered and evaporated. The crude product was purified by column chromatography on a 15 x 1 cm silica gel column and the alcohol VIIIa (X^3=Ac, Y^3=OH) was eluted with ethyl acetate hexane mixtures to give 1.4 mg (3 µmol) of product. Mass spectrum m/z (relative intensity) 476 (M^+) (1), 444 (85), 426 (18), 384 (30), 366 (48), 351 (21), 255 (35), 237 (48), 199 (100), 139 (51), 59 (58).

(e) 1α,25-Dihydroxy-19-nor-vitamin D_3(IIa, X^1= Y^1=H): The 10-alcohol (VIIIa, X^3=Ac, Y^3=OH) (1.4 mg) was dissolved in 100 µl anhydrous CH_2Cl_2 and 10 µl (14 µmol) triethylamine solution (prepared from 12 mg (16 µl) triethylamine in 100 µl anhydrous CH_2Cl_2), followed by 7 µl (5.6 µmol) methyl chloride solution (9 mg mesyl chloride, 6.1 µl, in 100 µl anhydrous CH_2Cl_2) added at 0°C. The mixture was stirred at 0°C for 2 h. The solvents were removed with a stream of argon and the residue (comprising compound VIIIa, X^3=Ac, Y^3=CH_3SO_2O-) dissolved in 0.5 ml of anhydrous tetrahydrofuran; 5 mg of $LiAlH_4$ was added at 0°C and the mixture kept at 0°C for 16 h. Excess $LiAlH_4$ was decomposed with wet ether, the ether phase was washed with water and dried over $MgSO_4$, filtered and evaporated to give the 19-nor product VIIIa (X^3=Y^3=H).

This product was dissolved in 0.5 ml of acetic acid and stirred at 55°C for 20 min. The mixture was cooled, ice water added and extracted with ether. The other phase was washed with cold 10% sodium bicarbonate solution, brine, dried over $MgSO_4$, filtered and evaporated to give the expected mixture of 3-acetoxy-1-α-hydroxy- and 1α-acetoxy-3-hydroxy isomers, which were separated and purified by HPLC (Zorbax Sil column, 6.4 x 25 cm, 2-propanol in hexane) to give about 70 µg each of compounds IXa and Xa. UV (in EtOH) λ_{max} 242.5 (OD 0.72), 251.5 (OD 0.86), 260 (OD 0.57).

Both 19-nor-1,25-dihydroxyvitamin D_3 acetates IXa and Xa were hydrolyzed in the same manner. Each of the monoacetates was dissolved in 0.5 ml of ether and 0.5 ml 0.1 N KOH in methanol was added. The mixture was stirred under argon atmosphere for 2 h. More ether was added and the organic phase washed with brine, dried over anhydrous $MgSO_4$, filtered and evaporated. The residue was dissolved in a 1:1 mixture of 2-propanol and hexane and passed through a Sep Pak column and washed with the same solvent. The solvents were evaporated and the residue purified by HPLC (Zorbax Sil, 6.4 x 25 cm, 10% 2-propanol in hexane). The hydrolysis products of IXa and Xa were identical and gave 66 µg of IIa (X^1=Y^1=H). Mass spectrum (mz relative intensity) 404 (M^+) (100), 386 (41), 371 (20), 275 (53), 245 (51), 180 (43), 135 (72), 133 (72), 95 (82), 59 (18), exact mass calcd. for $C_{26}H_{44}O_3$ 404.3290, found 404.3272. ^{1}H NMR ($CDCl_3$) δ 0.52 (3H, s, 18-CH_3), 0.92 (3H, d, J=6.9 Hz, 21-CH_3), 1.21 (6H, s, 26-CH_3 and 27-CH_3), 4.02 (1H, m, 3αH), 4.06 (1H, m, 1β-H), 5.83 (1H, d, J=11.6 Hz, 7-H), 6.29 (1H, d, J=10.7Hz, 6-H). UV (in EtOH), λ_{max} 243 (OD 0.725), 251.5 (OD 0.823), 261 (OD 0.598).

Example 2

Preparation of 1α-hydroxy-19-nor-vitamin D_3(IIb):

(a) With vitamin D_3 (IVb) as starting material, and utilizing the conditions of Example 1a, there is obtained known 1α-hydroxy-3,5-cyclovitamin D_3 1-acetate, 6-methyl ether, compound Vb (X^3=Ac).

(b) By subjecting intermediate Vb (X^3=Ac), as obtained in Example 2a above to the conditions of Example 1b, there is obtained 10,19-dihydro-1α,10-19-trihydroxy-3,5-cyclovitamin D_3 1-acetate, 6-methyl ether VIb (X^3=Ac).

(c) By treatment of intermediate VIb (X^3=Ac) with sodium metaperiodate according to Example 1c above, there is obtained 1α-hydroxy-10-oxo-3,5-cyclo-19-nor-vitamin D_3 1-acetat , 6-methyl ether VIIb (X^3=Ac).

(d) Upon r duction of th 10-oxo-intermediate VIIb (X^3=Ac) under the conditions f Example 1d abov , there is obtained 1α-acetoxy-10-hydroxy-3,5-cyclo-19-nor-vitamin D_3 6-methyl ether VIIIb (X^3=Ac, Y^3=OH).

( ) Upon processing int rmediate VIIIb (X^3=Ac, Y^3=OH) through the procedure given in Example 1e above, there is obtained 1α-hydroxy-19-nor-vitamin D_3 (IIb, X^1=Y^1=H).

Example 3

Preparation of 1α-hydroxy-19-nor-vitamin D_2:

(a) With vitamin D_2 (IVd) as starting material, and utilizing the conditions of Example 1a, there is obtained known 1α-hydroxy-3,5-cyclovitamin D_2 1-acetate, 6-methyl ether, compound Vd (X^3=Ac).

(b) By subjecting intermediate Vd (X^3=Ac), as obtained in Example 4a above to the conditions of Example 1b, there is obtained 10,19-dihydro-1α,10,19-trihydroxy-3,5-cyclovitamin D_2 1-acetate, 6-methyl ether, VId (X^3=Ac).

(c) By treatment of intermediate VId (X^3=Ac) with sodium metaperiodate according to Example 1c above, there is obtained 1α-hydroxy-10-oxo-3,5-cyclo-19-nor-vitamin D_2 1-acetate, 6-methyl ether, VIId (X^3=Ac).

(d) Upon reduction of the 10-oxo-intermediate VIId (X^3=Ac) under the conditions of Example 1d above, there is obtained 1α-acetoxy-10-hydroxy-3,5-cyclo-19-nor-vitamin D_2 6-methyl ether, VIIId (X^3=Ac, Y^3=OH).

(e) Upon processing intermediate VIIId (X^3=Ac, Y^3=OH) through the procedure given in Example 1e above, there is obtained 1α-hydroxy-19-nor-vitamin D_2 (IId, X^1=Y^1=H).

Compositions for use in the above-mentioned treatment of psoriasis and other malignancies comprise an effective amount of one or more 1α-hydroxy-19-nor-vitamin D compounds as defined by the above formula II as the active ingredient, and a suitable carrier. An effective amount of such compounds for use in accordance with this invention is from about 0.01 μg to about 100 μg per gm of composition, and may be administered topically, orally or parenterally in dosages of from about 0.1 μg/day to about 100 μg/day.

The compounds may be formulated as creams, lotions, ointments, topical patches, pills, capsules or tablets, or in liquid form as solutions, emulsions, dispersions or suspensions in pharmaceutically innocuous and acceptable solvent or oils, and such preparations may contain in addition other pharmaceutically innocuous or beneficial components, such as antioxidants or preserving agents, stabilising, wetting or emulsifying agents, solution promoters, coloring agents, binders or coating materials.

The compositions of this invention are typically formulated as a foam (which may contain a propellant), a stick, a cleansing pad, an impregnated wipe, a face pack, a shaving foam or an after shave, but preferably as creams, lotions or ointments by choice of appropriate carriers. Suitable carriers may be solid or liquid and include vegetable or mineral oils such as corn starch, lactose, sucrose, peanut oil, olive oil and sesame oil, propylene glycol, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohols (greater than C_{12}). The preferred carriers are those in which the active ingredient is soluble. Thickening agents (so that the composition is in the form of an ointment, cream, lotion or gel), other active cosmetic ingredients including anti-wrinkle agents and anti-grease agents along with additives such as surfactants, soaps, bath additives, organic solvents, emulsifiers, stabilizers and antioxidants may also be included as well as agents imparting color or fragrance if desired.

Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil such as almond oil, is admixed. A typical example of such a cream is one which includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.

Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil such as almond oil with warm soft paraffin and allowing the mixture to cool. A typical example of such an ointment is one which includes about 30% almond oil and about 70% white soft paraffin by weight.

Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol such as propylene glycol or polyethylene glycol.

The compounds may be administered topically, as oral doses, or parenterally by injection or infusion of suitable sterile solutions. The compounds are advantageously administered in amounts sufficient to effect the differentiation of promyelocytes to normal macrophages. Dosages as described above are suitable, it being understood that the amounts given are to be adjusted in accordance with the severity of the disease, and the condition and response of the subject as is well understood in the art. If a solid carrier is used the dosage form of the compounds is typically tablets, capsules, powders, troches or lozenges. If a liquid carrier is used, soft gelatin capsules, or syrup or liquid suspensions, emulsions or solutions may be the dosage form.

Biological activity of 1α-Hydroxy-19-Nor-Vitamin D Compounds

The 19-nor compounds of this invention exhibit a pattern of biological activity having high potency in promoting the differentiation of malignant cells and little or no activity in calcifying bone tissue. This is illustrated by the biological assay results obtained for 1α,25-dihydroxy-19-nor-vitamin D_3 which are summarized in Tables 1 and 2, respectively. As previously noted herein, this 1α,25-dihydroxy-19-nor compound is the metabolite of the 1α-hydroxy-19-nor compound that would fall within the structure of formula II. Table I shows a comparison of the activity of the known active metabolite 1α,25-dihydroxyvitamin D_3 and the 19-nor analog 1α,25-dihydroxy-19-nor-vitamin D_3 in inducing the differentiation of human leukemia cells (HL-60 cells) in culture to normal cells (monocytes). Differentiation activity was assessed by three standard differentiation assays, abbreviated in Table 2 as NBT (nitroblue tetrazolium reduction), NSE (non-specific esterase activity), and PHAGO (phagocytosis activity). The assays were conducted according to known procedures, as given, for example, by DeLuca et al. (U.S. Patent 4,717,721 and Ostrem et al., J. Biol. Chem. 262, 14164, 1987). For each assay, the differentiation activity of the test compounds is expressed in terms of the percent of HL-60 cells having differentiated to normal cells in response to a given concentration of test compound.

The results summarized in Table 1 clearly show that the analog, 1α,25-dihydroxy-19-nor-vitamin D_3 is as potent as 1α,25-dihydroxyvitamin D_3 in promoting the differentiation of leukemia cells. Thus in all three assays close to 90% of the cells are induced to differentiate by 1α,25-dihydroxy-vitamin D_3 at a concentration of 1 x 10^{-7} molar, and the same degree of differentiation (i.e. 90, 84 and 90%) is achieved by the 19-nor analog.

Table 1

Differentiation of HL-60 Cells

1α,25-dihydroxyvitamin D_3 (moles/liter)	% Differentiated Cells (mean ± SEM)		
	NBT	NSE	PHAGO
1×10^{-7}	86 ± 2	89 ± 1	87 ± 3
1×10^{-8}	60 ± 2	60 ± 3	64 ± 2
1×10^{-9}	33 ± 2	31 ± 2	34 ± 1
1α,25-Dihydroxy-19-nor-vitamin D_3 (moles/liter)			
2×10^{-7}	94 ± 2	95 ± 3	94 ± 2
1×10^{-7}	90 ± 4	84 ± 4	90 ± 4
5×10^{-8}	72 ± 3	73 ± 3	74 ± 3
1×10^{-8}	61 ± 3	60 ± 3	56 ± 1
1×10^{-9}	32 ± 1	31 ± 1	33 ± 1

In contrast to the preceding results, the 19-nor analog exhibits no activity in an assay measuring the calcification of bone, a typical response elicited by vitamin D compounds. Relevant data, representing the results of an assay comparing the bone calcification activity in rats of 1α,25-dihydroxyvitamin D_3 and 1α,25-dihydroxy-19-nor vitamin D_3 are summarized in Table 2. This assay was conducted according to the procedure described

by Tanaka et al., Endocrinology 92, 417 (1973).

The results presented in Table 2 show the expected bone calcification activity of 1α,25-dihydroxyvitamin D_3 as reflected by the increase in percent bone ash, and in total ash at all dose levels. In contrast, the 19-nor analog exhibits no activity at all three dose levels, when compared to the vitamin D-deficient (-D) control group.

Table 2

Calcification Activity

Compound	Amount Administered* (pmoles/day/7 days)	% Ash (mean ± SEM)	Total Ash (mg) (mean ± SEM)
-D (control)	0	19 ± 0.8	23 ± 1.2
1α,25-dihydroxy-vitamin D_3	32.5	23 ± 0.5	34 ± 1.6
	65.0	26 ± 0.7	36 ± 1.1
	325.0	28 ± 0.9	40 ± 1.9
1α,25-dihydroxy-19-nor-vitamin D_3	32.5	22 ± 0.9	28 ± 1.6
	65.0	19 ± 1.5	28 ± 3.4
	325.0	19 ± 1.2	30 ± 2.4

* Each assay group comprised 6 rats, receiving the indicated amount of test compound by intraperitoneal injection daily for a period of seven days.

Thus the 19-nor analog shows a selective activity profile combining high potency in inducing the differentiation of malignant cells with very low or no bone calcification activity. The compounds of this novel structural class, therefore, can be useful as therapeutic agents for the treatment of psoriasis and other malignancies.

It should be specifically noted that 1α-hydroxy-19-nor-vitamin D_3 is expected to be less active than 1α,25-dihydroxy-19-nor-vitamin D_3 in causing differentiation of HL60 cells in vitro. However, in vivo it is well established that 1α-hydroxy-19-nor-vitamin D_3 is rapidly converted to 1α,25-dihydroxy-19-nor-vitamin D_3, Hollick et al, Science, Vol. 190, pages 576-578 (1975) and Hollick et al, Journal of Clinical Endocrinology & Metabolism, Vol. 44, pages 595-598 (1977), which compound as shown herein is highly potent in cell differentiation. Thus, it is clear that the human body can rapidly convert the relatively inactive 1α-hydroxylated-19-nor-vitamin D compounds to metabolites highly active in causing cell differentiation. This in vivo capability makes possible the treatment of malignancies such as psoriasis with 1α-hydroxylated-19-nor-vitamin D compounds that do not initially have a hydroxyl group at the 24 or 25 carbon position in the side chain.

Claims

1. Use of a compound of formula I for the manufacture of a medicament for the treatment of psoriasis wherein formula I is:



I

where X and Y are each independently hydrogen, acyl alkylsilyl or alkoxyalkyl, and where U is selected from a side chain of the formula



wherein R_1 and R_2 are each independently alkyl, deuteroalkyl, hydroxyalkyl or fluoroalkyl, or, when taken together represent the group $-(CH_2)_m-$ where m is an integer having a value of from 2 to 5, R_3 is hydrogen, deuterium, hydroxy, fluorine, O-acyl, alkyl, hydroxyalkyl or fluoroalkyl, R_6 is hydrogen, deuterium, fluorine, alkyl, hydroxyalkyl or fluoroalkyl, or, R_3 and R_6 taken together represent double-bonded oxygen or double-bonded carbon, R_4 and R_5 are each independently hydrogen, deuterium, hydroxy, O-acyl, fluorine or alkyl or, R_4 and R_5 taken together form a carbon-carbon single bond or a carbon-carbon double bond, and wherein n is an integer having a value of form 1 to 5 and wherein the carbon at any one of positions 20, 22, or 23 in the side chain may be replaced by an O, S, or N atom.

2. Use according to claim 1 wherein the medicament contains 0.01 µg to 100 µg per gram of the compound.

3. Use according to claim 1 or 2 wherein the medicament is administered to a patient by topical, oral or parenteral means.

4. Use according to any one of the preceding claims wherein the medicament is used to provide an amount of the said compound of 0.1µg/day to 100µg/day.

5. A composition suitable for oral, topical or parenteral treatment of psoriasis which comprises a compound of formula I as defined in claim 1 and an appropriate carrier.

6. A composition according to claim 5 which contains 0.01 µg to 100 µg per gram of said compound.

7. A composition according to claims 5 or 6 in the form of a lotion.

8. A composition according to claims 5 or 6 in the form of a cream.

9. A composition according to claim 5 or 6 in the form of an ointment.

10. Use of a 1α-hydroxylat d-19-nor-vitamin D compound which c mpound upon administration to humans is c nverted to a m tabolite and said metabolit in vitro will cause differentiation in a c ll line for the manufacture of a medicament for th treatment of psoriasis.

11. Use according to claim 10 wherein said cell line is a U937 cell line, a HL60 cell line or a M1 cell line.

(19) Europäische Patentamt
European Patent Office
Office européen des brevets

(11) Publication number : **0 474 517 A3**

(12) EUROPEAN PATENT APPLICATION

(21) Application number : **91308205.3**

(51) Int. Cl.[5] : **A61K 31/59**

(22) Date of filing : **09.09.91**

(30) Priority : **07.09.90 US 579935**

(43) Date of publication of application :
11.03.92 Bulletin 92/11

(84) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(88) Date of deferred publication of search report :
10.06.92 Bulletin 92/24

(71) Applicant : **WISCONSIN ALUMNI RESEARCH FOUNDATION**
614 North Walnut Street
Madison, WI 53705 (US)

(72) Inventor : **DeLuca, Hector Floyd**
1809 Highway BB
Deerfield, Wisconsin 53531 (US)

(74) Representative : **Ellis-Jones, Patrick George Armine et al**
J.A. KEMP & CO. 14 South Square Gray's Inn
London WC1R 5LX (GB)

(54) Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis.

(57) A novel use for 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis inasmuch as these compounds when administered to humans are converted to a metabolite, such as a 1α,25-dihydroxylated compound, which metabolite in vitro will cause differentiation in a human cell line.

EP 0 474 517 A3

European Patent Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application Number: EP 91 30 8205

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	TETRAHEDRON LETTERS, vol. 31, no. 13, 3rd April 1990, pages 1823-1824, Pergamon Press plc; K.L. PERLMAN et al.: "1alpha,25-dihydroxy-19-nor-vitamin D3, a novel vitamin D-related compound with potential therapeutic activity" * Entire document *	1	A 61 K 31/59
Y	IDEM	2-9	
D,Y	WO-A-8 910 351 (LEO PHARMACEUTICAL PRODUCTS LTD) * Pages 1,16-19 *	2-9	
P,X	EP-A-0 387 077 (WISCONSIN ALUMNI RES. FOUNDATION) * Claims 1-8,21,22 *	1,5,10, 11	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A 61 K

INCOMPLETE SEARCH

The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims

Claims searched completely:

Claims searched incompletely: 10

Claims not searched:

Reason for the limitation of the search: It is not clear which compound is meant by "a metabolite" (claim 10).

Remark: "Although claim 4 is directed to a method of treatment of (diagnostic method practised on) the human/ animal body (Art. 52(4) EPC) the search has been carried out and based on the alleged effects of the compound/composition"

Place of search	Date of completion of the search	Examiner
THE HAGUE	09-03-1992	KLAVER T.

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P0407)